ADC Therapeutics SA — Form 8-K Summary
Reporting date: October 7, 2026; filed October 13, 2026. The filing reports a private placement and amendments to debt and royalty arrangements, and refers to preliminary third-quarter results.
Financial results and liquidity
The company says an October 8 press release contains preliminary, unaudited ZYNLONTA net product revenue for the quarter ended September 30, 2026, and preliminary cash and cash equivalents at that date. Those amounts are not included in the supplied filing text, so their values and changes from the prior-year quarter cannot be stated here. The company cautions that results are estimates, not finalized, and may differ materially from subsequently reported figures.
No profit, cash flow, margin, or full-period financial statements are provided in the supplied text.
Material financing and agreement changes
- Private placement: Agreements provide for sale of 12,911,347 common shares at $1.42 each and pre-funded warrants for 48,088,653 shares at $1.324 each. The company describes the transaction as $86.6 million assuming cash exercise of the warrants. Closing is expected October 22, 2026, subject to customary conditions. Resale registration is due within 30 business days.
- Pre-funded warrants: Exercisable through the tenth anniversary at CHF 0.08 per share, subject to customary adjustments and ownership limits. Cashless exercise is permitted, subject to the warrant terms.
- Loan amendment: Effectiveness requires prepayment of $70 million of term-loan principal, accrued interest and related fees and premiums, inclusive of the scheduled September 30 amortization payment. If made, $50 million principal would remain. The amendment eliminates subsequent scheduled principal amortization and the minimum-liquidity covenant, and sets a $65 million minimum trailing-four-quarter U.S. ZYNLONTA sales covenant beginning with the quarter ending December 31, 2026. Remaining principal is payable at maturity unless accelerated earlier.
- Lender warrants: Subject to the loan amendment becoming effective, exercise prices on warrants for 527,295 shares fall from $8.30 to $1.00 per share.
- HCR royalty agreement: HCR has provided $300 million of funding to date. The amendment removes a payment otherwise due solely upon a change of control and permits a royalty buyout for $525 million through December 31, 2029, or $750 million from January 1, 2030, in each case reduced by royalties previously paid. Without a buyout, royalties continue until the agreement’s Royalty Cap. The permitted aggregate third-party indebtedness is reduced to $50 million; an uncured breach may allow HCR to elect a specified non-performance payment, subject to a cure period.
- HCR warrants and corporate structure: Exercise prices on warrants for 9,834,776 shares fall from $3.813 to $0.10. The amendment adds ownership limits and removes certain transfer restrictions. It also requires best efforts, subject to shareholder approval and applicable duties, to become a Delaware corporation.
Outlook, conditions and risks
The financing and related amendments have interdependent conditions: the loan amendment requires the specified prepayment, and the HCR amendment requires completion of the private placement by October 31, 2026 and effectiveness of the loan amendment. The filing provides no broader operating or financial guidance. Key risks include closing and effectiveness conditions, potential dilution from the share issuance and warrants, the HCR debt-limit covenant and potential non-performance payment, and uncertainty in the preliminary results.
Investor facts to verify
- Whether the private placement closed and the final proceeds received.
- Final third-quarter ZYNLONTA revenue and September 30 cash balance in the subsequent results filing.
- Whether the $70 million loan prepayment occurred and the resulting debt balance and covenant terms.
- How the $50 million HCR indebtedness cap applies alongside the amended term loan.
- Potential dilution from the private-placement shares and pre-funded warrants, lender warrants, and HCR warrants.
- The HCR royalty buyout economics, remaining royalty cap, and any subsequent payments or covenant developments.